文献速递妇科

原发性腹膜癌、上皮性卵巢癌和输卵管癌患者中BRCA1/2致病变异位于卵巢癌聚集区的临床结局

Clinical outcomes of BRCA1/2 pathogenic variants in ovarian cancer cluster region in patients with primary peritoneal, epithelial ovarian, and fallopian tube cancer.
PubMed 文献 · Gynecol Oncol · 2021-12-17

回顾性分析991例接受BRCA1/2基因检测的上皮性卵巢癌、原发性腹膜癌和输卵管癌患者,比较致病变异位于卵巢癌聚集区(OCCR)与非OCCR区的生存结局。BRCA1 OCCR组无进展生存期短于非OCCR组(22.6个月 vs 27.6个月,P=0.038),铂敏感亚组中该趋势更明显(P=0.0197);BRCA2组无此趋势(32.8个月 vs 27.9个月,P=0.468);总生存期各组均无显著差异。

要点

  • BRCA1致病变异位于OCCR者无进展生存期短于非OCCR者(22.6个月 vs 27.6个月,P=0.038)。
  • BRCA1铂敏感亚组中OCCR组无进展生存期仍短于非OCCR组(P=0.0197)。
  • BRCA2致病变异位置与无进展生存期无关(32.8个月 vs 27.9个月,P=0.468)。

核心结论

  • BRCA1致病变异位于OCCR的患者无进展生存期短于非OCCR者,该趋势在铂敏感亚组中更明显。
  • BRCA2致病变异位置与无进展生存期无关,BRCA1/2致病变异位置与总生存期均无显著差异。
  • 作者称这是首个基于OCCR对BRCA1/2突变进行的研究。

研究设计与样本

  • 回顾性分析2006年1月1日至2019年8月31日接受BRCA1和/或BRCA2基因检测的991例上皮性卵巢癌、原发性腹膜癌和输卵管癌患者的病历。
  • 采用Sanger测序和二代测序分析BRCA1和BRCA2突变状态。
  • 按突变位置(OCCR区 vs 非OCCR区)比较无进展生存期和总生存期,采用Kaplan-Meier生存分析。

主要发现

  • 162例患者携带BRCA1致病变异,76例携带BRCA2致病变异。
  • BRCA1致病变异位于OCCR者无进展生存期短于非OCCR者(22.6个月 vs 27.6个月,P=0.038)。
  • BRCA1铂敏感亚组中,OCCR组无进展生存期短于非OCCR组(P=0.0197)。
  • BRCA2致病变异位置与无进展生存期无关(32.8个月 vs 27.9个月,P=0.468)。
  • BRCA1/2致病变异无论位置如何,总生存期均无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: An "ovarian cancer cluster region" (OCCR) has been reported in both BRCA1 and BRCA2. However, the clinical significance of the OCCR of BRCA1/2 has not yet been investigated. METHODS: The medical records of 991 patients with epithelial ovarian, primary peritoneal, and fallopian tube cancer who underwent genetic testing for BRCA1 and/or BRCA2 from January 1, 2006, to August 31, 2019, were retrospectively reviewed. Sanger and next-generation sequencing analyses were used to test the BRCA1 and BRCA2 mutation status. Progression-free survival (PFS) and overall survival (OS) were compared according to the mutation location (OCCR vs. non-OCCR region). Survival outcomes were determined using Kaplan-Meier survival analysis. RESULTS: A total of 162 patients had BRCA1 pathogenic variants (PVs), and 76 had BRCA2 PVs. Patients with BRCA1 PV that in the OCCR region showed shorter PFS than those with BRCA1 PV outside the OCCR (22.6 months vs. 27.6 months, P = 0.038). In the platinum-sensitive subgroup of BRCA1, patients with BRCA1 PV in the OCCR region showed shorter PFS than those in the non-OCCR group (P = 0.0197). On the other hand, BRCA2 variants did not exhibit any particular trend (32.8 months vs. 27.9 months, P = 0.468). However, no significant differences were detected in OS between patients with BRCA1/2 PVs, regardless of the location of the variants. CONCLUSIONS: Patients with BRCA1 PV in the OCCR had shorter PFS than those outside the OCCR. This tendency was more pronounced in the platinum-sensitive subgroup. To our knowledge, this is the first study of BRCA1/2 mutations based on the OCCR.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Ha HI, Park EY, Eoh KJ, et al. Clinical outcomes of BRCA1/2 pathogenic variants in ovarian cancer cluster region in patients with primary peritoneal, epithelial ovarian, and fallopian tube cancer. Gynecol Oncol. 2021. PMID: 34924242. doi:10.1016/j.ygyno.2021.12.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。